Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyLoteprednol
Identification
- Name
- Loteprednol
- Accession Number
- DB00873 (APRD01078)
- Type
- Small Molecule
- Groups
- Approved
- Description
Loteprednol (as Loteprednol Etabonate) is a topical corticoid antiinflammatory. It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, is used for the treatment and management of seasonal allergic rhinitis.
- Structure
Structure for DB00873 (Loteprednol)
- Synonyms
- Loteprednol
- Loteprednolum
- External IDs
- CDDD 5604 / HGP 1 / P 5604
- Product Ingredients
Ingredient UNII CAS InChI Key Loteprednol etabonate YEH1EZ96K6 82034-46-6 DMKSVUSAATWOCU-HROMYWEYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Alrex Suspension / drops 2 mg/mL Ophthalmic Bauch & Lomb Incorporated 1998-03-09 Not applicable US 
Alrex Suspension / drops 2 mg/mL Ophthalmic Stat Rx USA 1998-03-09 2018-02-08 US Alrex Suspension / drops 2 mg/mL Ophthalmic Physicians Total Care, Inc. 2002-10-17 Not applicable US Alrex Suspension 0.2 % Ophthalmic Bausch & Lomb Inc 2009-06-24 Not applicable Canada 
Lotemax Ointment 5 mg/g Ophthalmic Bauch & Lomb Incorporated 2011-04-15 Not applicable US Lotemax Suspension / drops 5 mg/mL Ophthalmic Physicians Total Care, Inc. 2002-10-17 Not applicable US Lotemax Gel 5 mg/g Ophthalmic Bauch & Lomb Incorporated 2012-10-12 Not applicable US Lotemax Suspension 0.5 % Ophthalmic Bausch & Lomb Inc 2009-06-24 Not applicable Canada Lotemax Suspension / drops 5 mg/mL Ophthalmic Bauch & Lomb Incorporated 1998-03-09 Not applicable US Lotemax Gel Gel 0.5 % Ophthalmic Bausch & Lomb Inc 2015-06-25 Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Zylet Loteprednol etabonate (5 mg/mL) + Tobramycin (3 mg/mL) Suspension / drops Ophthalmic Bauch & Lomb Incorporated 2004-12-14 Not applicable US - International/Other Brands
- Loteflam (Cipla Pharmaceuticals Limited)
- Categories
- UNII
- Z8CBU6KR16
- CAS number
- 129260-79-3
- Weight
- Average: 394.889
Monoisotopic: 394.154701681 - Chemical Formula
- C21H27ClO5
- InChI Key
- YPZVAYHNBBHPTO-MXRBDKCISA-N
- InChI
- InChI=1S/C21H27ClO5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,18(25)27-11-22)20(15,2)10-16(24)17(14)19/h5,7,9,14-17,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17+,19-,20-,21-/m0/s1
- IUPAC Name
- chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-diene-14-carboxylate
- SMILES
- [H][[email protected]@]12CC[[email protected]](O)(C(=O)OCCl)[[email protected]@]1(C)C[[email protected]](O)[[email protected]@]1([H])[[email protected]@]2([H])CCC2=CC(=O)C=C[[email protected]]12C
Pharmacology
- Indication
As an ophthalmic it is used for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides. As a nasal spray, used for the treatment and management of seasonal allergic rhinitis.
- Structured Indications
- Pharmacodynamics
Loteprednol etabonate (LE) is a "soft" steroid belonging to a unique class of glucocorticoids. LE possesses a metabolically labile 17 beta-chloromethyl ester function which was designed in order to be hydrolyzed to an inactive carboxylic acid moiety. This inactive metabolite is more hydrophilic and is thus readily eliminated from the body. Loteprednol etabonate has good ocular permeation properties and good skin permeation properties similar to "hard" steroids. It is used as a topical agent for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis and iritis.
- Mechanism of action
Loteprednol etabonate (LE) is a "soft" steroid belonging to a unique class of glucocorticoids. Loteprednol etabonate is structurally similar to other glucocorticoids. However, the number 20 position ketone group is absent. It is highly lipid soluble which enhances its penetration into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone- related compounds so that it will undergo a predictable transformation to an inactive metabolite. It first binds to the type II glucocorticoid receptor. Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Target Actions Organism AGlucocorticoid receptor agonistHuman - Absorption
Very limited systemic absorption, but good absorption at the point of delivery.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
The drugs 17 beta-chloromethyl ester function is hydrolyzed to an inactive carboxylic acid moiety.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Adverse effects include abnormal vision / blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Loteprednol. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Loteprednol is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Loteprednol. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Loteprednol. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Loteprednol. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Loteprednol. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Loteprednol. Approved, Withdrawn Aldesleukin Loteprednol may decrease the antineoplastic activities of Aldesleukin. Approved Almasilate The bioavailability of Loteprednol can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Loteprednol. Experimental Aloglutamol The bioavailability of Loteprednol can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Loteprednol. Experimental Aluminium The bioavailability of Loteprednol can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of Loteprednol can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Loteprednol can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Loteprednol can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when Loteprednol is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Loteprednol. Approved Amiodarone The serum concentration of Loteprednol can be increased when it is combined with Amiodarone. Approved, Investigational Amphotericin B Loteprednol may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Loteprednol. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Loteprednol. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Loteprednol is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Loteprednol. Approved, Investigational Apalutamide The serum concentration of Loteprednol can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Loteprednol. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Loteprednol. Approved, Investigational Aprepitant The serum concentration of Loteprednol can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Loteprednol can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Loteprednol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Loteprednol. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Loteprednol. Approved Azosemide Loteprednol may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Loteprednol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Loteprednol is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Loteprednol. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Loteprednol is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Loteprednol. Experimental Bendroflumethiazide Loteprednol may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Loteprednol. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Loteprednol. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Loteprednol. Approved, Investigational Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Loteprednol. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Loteprednol. Experimental Bismuth Subcitrate The bioavailability of Loteprednol can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of Loteprednol can be decreased when combined with Bismuth subnitrate. Approved, Experimental Boceprevir The serum concentration of Loteprednol can be increased when it is combined with Boceprevir. Approved, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Loteprednol. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Loteprednol. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Loteprednol. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Loteprednol. Experimental Bumetanide Loteprednol may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Loteprednol. Approved, Nutraceutical Calcium Carbonate The bioavailability of Loteprednol can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of Loteprednol can be decreased when combined with Calcium silicate. Experimental Capromab pendetide Loteprednol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Loteprednol can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Loteprednol. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Loteprednol. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Loteprednol. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Loteprednol. Approved, Investigational Ceritinib Loteprednol may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Loteprednol. Approved, Investigational, Vet Approved Chlorothiazide Loteprednol may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Loteprednol can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorthalidone Loteprednol may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Loteprednol. Approved Cinoxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Cinoxacin. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Loteprednol can be increased when it is combined with Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Loteprednol. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Loteprednol is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of Loteprednol can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of Loteprednol can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Loteprednol. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Loteprednol is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Loteprednol is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Loteprednol. Approved, Investigational Cyclopenthiazide Loteprednol may increase the hypokalemic activities of Cyclopenthiazide. Experimental Daidzein The serum concentration of Loteprednol can be increased when it is combined with Daidzein. Experimental Danazol Loteprednol may increase the fluid retaining activities of Danazol. Approved Darunavir The serum concentration of Loteprednol can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when Loteprednol is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Loteprednol is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when Loteprednol is combined with Demecarium. Approved Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with Loteprednol. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Loteprednol is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Loteprednol. Approved, Vet Approved Dienestrol The serum concentration of Loteprednol can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Loteprednol can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Loteprednol. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Loteprednol. Approved, Investigational Distigmine The risk or severity of adverse effects can be increased when Loteprednol is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Loteprednol is combined with Donepezil. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Loteprednol. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Loteprednol. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Loteprednol. Investigational Echothiophate The risk or severity of adverse effects can be increased when Loteprednol is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Loteprednol is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Loteprednol can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Loteprednol can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Loteprednol. Approved Epitizide Loteprednol may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of Loteprednol can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of Loteprednol can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Loteprednol can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Loteprednol can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Loteprednol can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Loteprednol can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Loteprednol can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Loteprednol can be increased when it is combined with Estrone. Approved Etacrynic acid Loteprednol may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Loteprednol. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Loteprednol. Experimental Ethinyl Estradiol The serum concentration of Loteprednol can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Loteprednol. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Loteprednol. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Loteprednol. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Loteprednol. Approved, Investigational Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Loteprednol. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Loteprednol. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Loteprednol. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Loteprednol. Approved Fenthion The risk or severity of adverse effects can be increased when Loteprednol is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Loteprednol. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Loteprednol. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Loteprednol. Experimental Fleroxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Loteprednol. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when Loteprednol is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Loteprednol. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Loteprednol. Experimental Fluoxymesterone Loteprednol may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Loteprednol. Approved, Investigational Fosaprepitant The serum concentration of Loteprednol can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Loteprednol can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide Loteprednol may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Loteprednol is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Loteprednol is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Loteprednol is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Loteprednol can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Loteprednol is combined with GI-5005. Investigational GLPG-0492 Loteprednol may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Loteprednol. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Loteprednol. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Loteprednol. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Loteprednol is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Loteprednol is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of Loteprednol can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Loteprednol. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Loteprednol is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when Loteprednol is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Loteprednol. Approved, Investigational Hydrochlorothiazide Loteprednol may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Loteprednol may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of Loteprednol can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Loteprednol. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Loteprednol. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Loteprednol. Approved, Investigational Idelalisib The serum concentration of Loteprednol can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Loteprednol. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Loteprednol. Approved Indapamide Loteprednol may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Loteprednol can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Loteprednol. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Loteprednol. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Loteprednol. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Loteprednol is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Loteprednol is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when Loteprednol is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when Loteprednol is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Loteprednol. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Loteprednol. Withdrawn Itraconazole The serum concentration of Loteprednol can be increased when it is combined with Itraconazole. Approved, Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Loteprednol is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Loteprednol. Experimental Ketoconazole The serum concentration of Loteprednol can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Loteprednol. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Loteprednol. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Loteprednol. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Loteprednol. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Loteprednol. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Loteprednol. Experimental Lopinavir The serum concentration of Loteprednol can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Loteprednol. Approved, Investigational Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Loteprednol. Approved, Investigational Lumacaftor The serum concentration of Loteprednol can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Loteprednol. Approved, Investigational Magaldrate The bioavailability of Loteprednol can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium hydroxide The bioavailability of Loteprednol can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of Loteprednol can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Loteprednol can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loteprednol. Approved Magnesium silicate The bioavailability of Loteprednol can be decreased when combined with Magnesium silicate. Approved, Experimental Magnesium Trisilicate The bioavailability of Loteprednol can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Loteprednol is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Loteprednol. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loteprednol. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Loteprednol. Approved Mefloquine The risk or severity of adverse effects can be increased when Loteprednol is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Loteprednol. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Loteprednol is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Loteprednol. Approved Mesterolone Loteprednol may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Loteprednol can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Loteprednol. Approved, Investigational, Withdrawn Methallenestril The serum concentration of Loteprednol can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Loteprednol is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Loteprednol may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Loteprednol. Approved, Vet Approved Methyltestosterone Loteprednol may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Loteprednol is combined with Metoclopramide. Approved, Investigational Metolazone Loteprednol may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of Loteprednol can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Loteprednol is combined with Minaprine. Approved Mitotane The serum concentration of Loteprednol can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Loteprednol. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Loteprednol. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Loteprednol. Experimental Moxestrol The serum concentration of Loteprednol can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Loteprednol. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loteprednol. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Loteprednol. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Loteprednol. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Loteprednol. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Loteprednol is combined with Nalidixic Acid. Approved, Investigational Nandrolone Loteprednol may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate Loteprednol may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Loteprednol. Approved, Vet Approved Nefazodone The serum concentration of Loteprednol can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Loteprednol can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Loteprednol is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Loteprednol. Approved, Investigational Nevirapine The serum concentration of Loteprednol can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when Loteprednol is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Loteprednol. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Loteprednol. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Loteprednol. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Loteprednol. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Norfloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Loteprednol. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Loteprednol. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Loteprednol. Vet Approved Oxandrolone Loteprednol may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Loteprednol. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Loteprednol is combined with Oxolinic acid. Experimental Oxymetholone Loteprednol may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loteprednol. Approved, Withdrawn Paraoxon The risk or severity of adverse effects can be increased when Loteprednol is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Loteprednol. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Loteprednol. Approved, Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Loteprednol can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The serum concentration of Loteprednol can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Loteprednol. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Loteprednol. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Loteprednol. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Loteprednol. Approved, Investigational Phenytoin The serum concentration of Loteprednol can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Loteprednol is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loteprednol. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Loteprednol is combined with Pipemidic acid. Experimental Piretanide Loteprednol may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Loteprednol. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when Loteprednol is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Loteprednol. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Loteprednol. Experimental Polyestradiol phosphate The serum concentration of Loteprednol can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Loteprednol may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The serum concentration of Loteprednol can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Loteprednol. Experimental, Investigational Primidone The serum concentration of Loteprednol can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Loteprednol. Experimental Promestriene The serum concentration of Loteprednol can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Loteprednol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Loteprednol. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Loteprednol. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Loteprednol. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Loteprednol is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of Loteprednol can be increased when it is combined with Quinestrol. Approved Quinethazone Loteprednol may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Loteprednol is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Loteprednol. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Loteprednol. Approved, Experimental, Investigational Rifabutin The serum concentration of Loteprednol can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Loteprednol can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Loteprednol can be decreased when it is combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Loteprednol is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when Loteprednol is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Loteprednol. Approved, Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Rosoxacin. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when Loteprednol is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Loteprednol is combined with Rubella virus vaccine. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Loteprednol. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Loteprednol. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Loteprednol is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Loteprednol is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Loteprednol. Approved Saquinavir The serum concentration of Loteprednol can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of Loteprednol can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Loteprednol. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Loteprednol. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Loteprednol. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Sitafloxacin. Experimental, Investigational Sodium bicarbonate The bioavailability of Loteprednol can be decreased when combined with Sodium bicarbonate. Approved Sparfloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Loteprednol is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Loteprednol. Investigational St. John's Wort The serum concentration of Loteprednol can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Loteprednol may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol Loteprednol may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Loteprednol can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Loteprednol. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Loteprednol. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Loteprednol. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Loteprednol. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Loteprednol can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Loteprednol can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Loteprednol is combined with Tacrine. Investigational, Withdrawn Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Loteprednol. Investigational Tecemotide The risk or severity of adverse effects can be increased when Loteprednol is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Loteprednol. Approved, Withdrawn Telithromycin The serum concentration of Loteprednol can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Loteprednol. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Loteprednol. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Loteprednol. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Loteprednol. Approved Testosterone Loteprednol may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Loteprednol. Approved Testosterone enanthate The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Loteprednol. Approved Testosterone propionate Loteprednol may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Loteprednol. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Loteprednol is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Loteprednol. Approved Tibolone The serum concentration of Loteprednol can be increased when it is combined with Tibolone. Approved, Investigational Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Loteprednol. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Loteprednol. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Loteprednol. Approved Torasemide Loteprednol may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Loteprednol. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Loteprednol. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Loteprednol is combined with Trichlorfon. Vet Approved Trichlormethiazide Loteprednol may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Loteprednol. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Loteprednol. Approved Tromethamine The bioavailability of Loteprednol can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Loteprednol is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Loteprednol is combined with Tubocurarine. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Loteprednol. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Loteprednol is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Voriconazole The serum concentration of Loteprednol can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Loteprednol may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Loteprednol is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loteprednol. Approved, Investigational Zeranol The serum concentration of Loteprednol can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Loteprednol. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Loteprednol. Withdrawn - Food Interactions
- Not Available
References
- General References
- Pavesio CE, Decory HH: Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9. doi: 10.1136/bjo.2007.132621. Epub 2008 Feb 1. [PubMed:18245274]
- External Links
- Human Metabolome Database
- HMDB0015011
- KEGG Drug
- D01689
- PubChem Compound
- 9865442
- PubChem Substance
- 46504713
- ChemSpider
- 8041134
- ChEBI
- 50848
- Therapeutic Targets Database
- DAP001045
- PharmGKB
- PA164764569
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Loteprednol
- ATC Codes
- S01BA14 — Loteprednol
- AHFS Codes
- 52:08.08 — Corticosteroids
- FDA label
- Download (1.1 MB)
- MSDS
- Download (57.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Bausch and lomb inc
- Pharmos corp
- Packagers
- Alchymars SPA
- Bausch & Lomb Inc.
- Physicians Total Care Inc.
- Dosage forms
Form Route Strength Suspension Ophthalmic 0.2 % Suspension / drops Ophthalmic 2 mg/mL Gel Ophthalmic 5 mg/g Ointment Ophthalmic 5 mg/g Suspension Ophthalmic 0.5 % Suspension / drops Ophthalmic 5 mg/mL Gel Ophthalmic 0.5 % Ointment Ophthalmic 0.5 % Suspension / drops Ophthalmic - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5540930 No 1993-10-25 2013-10-25 US US4996335 No 1995-03-09 2012-03-09 US CA2174550 No 2002-10-01 2014-10-21 Canada US5800807 No 1997-01-29 2017-01-29 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 220-224 °C Not Available water solubility 5 mg/mL Not Available logP 3.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0336 mg/mL ALOGPS logP 2.2 ALOGPS logP 2.52 ChemAxon logS -4.1 ALOGPS pKa (Strongest Acidic) 12.01 ChemAxon pKa (Strongest Basic) -2.9 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 83.83 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 102.65 m3·mol-1 ChemAxon Polarizability 41.29 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9884 Blood Brain Barrier + 0.9294 Caco-2 permeable + 0.5426 P-glycoprotein substrate Substrate 0.7489 P-glycoprotein inhibitor I Non-inhibitor 0.6379 P-glycoprotein inhibitor II Non-inhibitor 0.6419 Renal organic cation transporter Non-inhibitor 0.7633 CYP450 2C9 substrate Non-substrate 0.862 CYP450 2D6 substrate Non-substrate 0.914 CYP450 3A4 substrate Substrate 0.794 CYP450 1A2 substrate Non-inhibitor 0.8987 CYP450 2C9 inhibitor Non-inhibitor 0.8866 CYP450 2D6 inhibitor Non-inhibitor 0.872 CYP450 2C19 inhibitor Non-inhibitor 0.9233 CYP450 3A4 inhibitor Non-inhibitor 0.5687 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8468 Ames test Non AMES toxic 0.8574 Carcinogenicity Non-carcinogens 0.9436 Biodegradation Not ready biodegradable 0.9614 Rat acute toxicity 2.2305 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9647 hERG inhibition (predictor II) Non-inhibitor 0.5773
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives show 4 more
- Substituents
- Androgen-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / Oxosteroid / Hydroxysteroid / Delta-1,4-steroid / Tertiary alcohol show 18 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- organochlorine compound, 11beta-hydroxy steroid, 17alpha-hydroxy steroid, androstanoid, 3-oxo-Delta(1),Delta(4)-steroid, steroid acid ester (CHEBI:50848)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Druzgala P, Hochhaus G, Bodor N: Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991 Feb;38(2):149-54. [PubMed:2004037]
- Bodor N, Buchwald P: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des. 2006;12(25):3241-60. [PubMed:17020532]
- Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. [PubMed:12861354]
- Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr: Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther. 2004 Dec;20(6):533-47. [PubMed:15684812]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:01